

CEO

Severin Schwan

Chairman of the Board

Franz B. Humer

Headquarters

Basel, Switzerland

Company Structure**Pharmaceuticals**

United States

Western Europe

Japan

International

Diagnostics

Roche Applied Sciences

Roche Molecular Diagnostics

Roche Professional

Roche Tissue Diagnostics

Roche Diabetes Care

Major R&D sites

Basel

Nutley

Penzberg

Focus

Metabolism, Central Nervous System

Oncology Inflammation, Virology

Diagnostics

Mannheim

Rotkreuz

Pleasanton

Ventana Medical Systems (Tucson, Arizona)

Shanghai

South San Francisco

Chugai (Tokyo)

Diagnostics/Diabetes Care

Diagnostics

Molecular Diagnostics

Tissue Diagnostics

China R&D Center

Genentech Research&Early Dev.

Major production sites	Roche's global Pharma Manufacturing network consists of 21 plant operations at 17 sites
Web site address	www.roche.com
Stock exchange listings	SWX Swiss Exchange
2010 Sales	47.53 billion Swiss francs
Pharmaceuticals	37.1 billion Swiss francs
Diagnostics	10.4 billion Swiss francs
R&D 2010	Group expenditure 9 billion Swiss francs
Pipeline Pharmaceuticals 2010	102 clinical projects (phase I to III and filed for regulatory review); including 62 new molecular entities (NMEs) and 40 additional indications. 18 major approvals gained.
Pipeline Diagnostics 2010	39 new tests launched in the area of infectious diseases and Virology Important medical data generated: ATHENA on HPV detection in cervical cancer PROTECT on heart insufficiency STeP on improved diabetes management
Number of employees 2010	Over 80.000 worldwide